GOODWILL(SH:688246) Zhong Guo Jing Ji Wang·2025-09-29 08:28Core Viewpoint - 嘉和美康's financial performance in the first half of 2025 shows significant declines in revenue and net profit, indicating ongoing challenges for the company [1][2]. Financial Performance Summary - In the first half of 2025, 嘉和美康 reported revenue of 2.19 billion yuan, a decrease of 27.22% year-on-year [1][2]. - The net profit attributable to shareholders was -1.16 billion yuan, and the net profit after deducting non-recurring gains and losses was -1.18 billion yuan [1][2]. - The net cash flow from operating activities was -1.68 billion yuan [1][2]. Previous Year Comparison - For the year 2024, 嘉和美康 achieved revenue of 5.92 billion yuan, down 14.85% from 2023 [3]. - The net profit attributable to shareholders for 2024 was -2.56 billion yuan, compared to a profit of 32.28 million yuan in the previous year [3]. - The net cash flow from operating activities for 2024 was -67.63 million yuan [3]. IPO and Fundraising - 嘉和美康 raised a total of 1.362 billion yuan from its initial public offering, with a net amount of 1.24 billion yuan after deducting issuance costs [4]. - The company initially planned to raise 750 million yuan for various projects, including electronic medical record development and data center upgrades [4].